

# Provider Update

## Immune Globulin Home Infusion Therapy Part B coverage reminder

**Background:** Amerigroup\* reminds providers that the Centers for Medicare & Medicaid Services (CMS) requires that intravenous immune globulin<sup>1</sup> administered in the home setting is only covered under the Medicare Part B benefit when associated with primary immune deficiency disease.<sup>1</sup> Intravenous immune globulin provided for any other diagnosis in the home setting will not be covered under the member's Part B benefit.

✦ **What this means to you:** Home infusion providers should submit intravenous immune globulin drug reimbursement claims to the members' Medicare Part D benefit for all indications other than primary immune deficiency disease.

### **Additional information and tools**

Please see CMS' Medicare Prescription Drug Benefit Manual for more information at:

- [www.cms.gov/PrescriptionDrugCovContra/Downloads/Chapter6.pdf](http://www.cms.gov/PrescriptionDrugCovContra/Downloads/Chapter6.pdf)

### **What if I need assistance?**

If you have questions about this communication, received this fax in error or need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-866-805-4589.

\*In Texas, Amerigroup members in the Medicaid Rural Service Area are served by Amerigroup Insurance Company; all other Amerigroup members are served by Amerigroup Texas, Inc.

<sup>1</sup> Immune globulin is defined by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 as an approved pooled plasma derivative: IVIG, SCIG, IMIG.

<sup>1</sup> And meets medical necessity criteria

Amerivantage is an HMO plan with a Medicare contract and a contract with the Texas Medicaid program. Enrollment in Amerivantage depends on contract renewal.

WEB-SSO-0040-15

January 2015

by Amerigroup Specialty Products Group

1145036 01 2015

